In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
News|Articles|May 28, 2026
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
Author(s)Russ Conroy
Fact checked by: Roman Fabbricatore
Presentations at the 2026 ASCO Annual Meeting may reveal key advances in the use of different bispecific antibodies and CELMoDs in multiple myeloma care.
Advertisement
Advertisement
The
Related to this article
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
Ryosuke Tateishi, MD, PhD, discussed lifestyle interventions, surveillance, and what the US and Japan can share to prevent MASLD-related liver cancer.
At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
Advertisement
Advertisement